All In Biotech

NDA 021938 · Cppi Cv

Sutent

Sunitinib Malate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jan 26, 2006

Approved uses

9

Original approval plus efficacy supplements

Registered trials

500

58 Phase 3, 25 recruiting

FAERS reports

39,149

30,215 serious, 11,688 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1) ].

What it is approved for

From the label in effect Feb 20, 2026.

SUTENT is a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.

Mechanism: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SUTENT · SUNITINIB MALATE EQ 50MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • SUTENT · SUNITINIB MALATE EQ 12.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • SUTENT · SUNITINIB MALATE EQ 37.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • SUTENT · SUNITINIB MALATE EQ 25MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sunitinib Malate" as an intervention, any sponsor and status, largest first.

All 500 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death7,452
  • diarrhoea4,422
  • fatigue4,195
  • disease progression3,912
  • nausea3,121
  • asthenia2,461
  • decreased appetite2,316
  • vomiting2,211
  • neoplasm progression2,020
  • hypertension1,805
  • dysgeusia1,696
  • weight decreased1,589

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
2006777
2007810
2008838
20091,585
20103,423
20112,736
20123,177
20132,701
20143,143
20153,905
20163,384
20172,986
20182,531
20192,041
20201,594
20211,172
20221,066
2023508
2024314
2025269
2026188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sutent (Sunitinib Malate)

2024 spending

$4.6M

Beneficiaries

78

364 claims

Per beneficiary

$59,222

$514.66 per unit

View as table
YearSpending
2020$120,222,574
2021$96,954,410
2022$17,597,961
2023$7,397,129
2024$4,619,328

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Cppi Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.